Meta‐analysis of clinically available pharmacotherapy of biopsy confirmed metabolic dysfunction associated steatohepatitis ( MASH )

作者
Emily M. Wood,Rukayat Akande,Iqra Iqbal,Stewart G. Albert
出处
期刊:Diabetes, Obesity and Metabolism [Wiley]
卷期号:28 (2): 1266-1277
标识
DOI:10.1111/dom.70314
摘要

Abstract Aims Pharmacotherapy for metabolic associated steatotic liver disease (MASLD) is reserved for steatohepatitis (MASH) with moderate Fibrosis Grades 2–3. Randomised controlled trials (RCT) of clinically available medications with biopsy data were evaluated for treatment benefits in steatohepatitis. Materials and Methods PUBMED, Cochrane, and Scopus databases were searched for ‘MASH/NASH/NAFLD/randomised‐controlled trials/liver biopsy’ ( N = 848 publications) which provided 14 publications with biopsy data. Outcomes were changes in biopsy MASLD Activity Scores (MAS), Fibrosis Grades, resolution of MASH with no worsening of liver fibrosis (RSw/oF) or reduction ≥1 fibrosis stage with no worsening of steatohepatitis (RFw/oS). Meta‐analyses and meta‐regression analyses were performed. Results There were 3173 subjects (age 53.1 ± 5.8 SD years). Steatohepatitis scores (MAS) improved with treatment versus placebo by mean difference (md) = −1.27 ± 0.16 SD Units, p < 0.001. MAS sub scores improved for steatosis, lobar inflammation, and ballooning for dapagliflozin, semaglutide, and pioglitazone (all p < 0.002). Fibrosis Grades improved compared to placebo (md = −0.352 ± 0.03 Units, p < 0.001). Relative rates (rr) of RSw/oF and RFw/oS were found with resmetirom, semaglutide, tirzepatide, and dapagliflozin (all p < 0.015). Changes in RSw/oF and RFw/oS inversely correlated with the baseline levels of Fibrosis Grades ( p = 0.025, and p = 0.076 respectively), with greater improvements of both at lower Fibrosis Grades. Conclusions Clinically available medications are beneficial in reversing MASH. Improvements in RSw/oF and RFw/oS were greater at earlier stages of fibrosis. Future analyses of drug effects should include assessments adjusted for baseline study characteristics of Fibrosis Grades and may evaluate whether preventive therapy will have long term benefits if started at earlier stages of MASLD.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
香蕉觅云的应助被11采纳,获得10
刚刚
1秒前
科研通AI6.4的应助被胡萝卜卜采纳,获得10
1秒前
2秒前
豆腐鱼发布了新的文献求助10
2秒前
pluto的应助被科研通管家采纳,获得10
2秒前
在水一方的应助被科研通管家采纳,获得10
2秒前
xing_xing的应助被科研通管家采纳,获得20
2秒前
上官若男的应助被科研通管家采纳,获得10
2秒前
xing_xing的应助被科研通管家采纳,获得20
2秒前
Jasper的应助被科研通管家采纳,获得10
3秒前
syvshc的应助被不灵0采纳,获得10
3秒前
xing_xing的应助被科研通管家采纳,获得20
3秒前
bkagyin的应助被fjw采纳,获得10
3秒前
ohh完成签到 ,获得积分10
3秒前
搜集达人的应助被科研通管家采纳,获得10
3秒前
Ava的应助被科研通管家采纳,获得10
3秒前
3秒前
充电宝的应助被科研通管家采纳,获得10
3秒前
4秒前
星野发布了新的文献求助10
5秒前
6秒前
万能图书馆的应助被11采纳,获得10
6秒前
dit完成签到,获得积分20
6秒前
syvshc的应助被苦瓜采纳,获得10
6秒前
火星上的笑珊完成签到 ,获得积分20
7秒前
CodeCraft的应助被zzz采纳,获得10
8秒前
斯文败类的应助被玉玉玉米采纳,获得10
8秒前
8秒前
斯文败类的应助被玉玉玉米采纳,获得10
8秒前
共享精神的应助被玉玉玉米采纳,获得10
8秒前
果果123发布了新的文献求助10
8秒前
8秒前
无聊的思烟完成签到 ,获得积分10
9秒前
顾矜的应助被Conqurd采纳,获得10
9秒前
dit发布了新的文献求助10
9秒前
苦哈哈完成签到 ,获得积分10
9秒前
10秒前
pear发布了新的文献求助10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194332
求助须知:如何正确求助?哪些是违规求助? 9580146
关于积分的说明 21869842
捐赠科研通 7793919
什么是DOI,文献DOI怎么找? 3437579
关于科研通互助平台的介绍 2560986
邀请新用户注册赠送积分活动 2484371